• Donors/Contributors
• Conferences
• Research
• Contact Us

• Neurology Home
• Facilities
  • University of Utah Hospital
  • Primary Children's Medical Center
  • Wahlen Veterans Administration Hospital
  • Eccles Institute of Human Genetics
  • Moran Eye Center
  • Eccles Health Sciences Library
  • Laboratories
  • Huntsman Cancer Institute & Hospital
  • Clinical Neurosciences Center
• Residency Training
  • Letter from the Chair
  • Letter from the Director
  • Residency Overview
  • Application Information
  • Meet Our Current Residents
  • Current Resident & Fellow Research
• Fellowship Training
  • Clinical Neurophysiology
  • Fellowship Training
  • Neuro-Opthalmology
  • Neuro-Genetics
  • Meet Our Current Fellows
  • Stroke / Neurovascular Fellowship
  • Neurocritical Care
• Student Electives
• Faculty & Staff
• Specialties
  • Peripheral Neuropathy Research Group
  • Pediatric Motor Disorders
  • Sleep Wake Center
  • Center for Alzheimer's Care
• Salt Lake Living
• Neurology Alumni

John M. Hoffman, MD

Professor of Neurology and Radiology

Director of Nuclear Medicine

Director of Molecular Imaging Program, Huntsman Cancer Institute

Willard Snow Hansen Presidential Endowed Chair in Cancer Research

Dr. John M. Hoffman is Professor of Radiology and Neurology. He is the Willard Snow Hansen Presidential Endowed Chair in Cancer Research, Director of Nuclear Medicine, and Director of the Molecular Imaging Program at the Huntsman Cancer Institute at the University of Utah.

Dr. Hoffman received his undergraduate degree from the University of Pennsylvania, graduating magna cum laude with a degree in biomedical engineering. He received his MD from the University of Colorado. He completed two years of training in Neurosurgery and then a neurology residency at the University of Washington in Seattle. Dr Hoffman then completed a Nuclear Medicine and PET fellowship at UCLA Medical Center. He has been on the faculties of Duke and Emory Universities. Prior to assuming his position at the University of Utah in 2005, he was Chief of the Molecular Imaging Branch of the Cancer Imaging Program at NCI/NIH.

He has a particular interest in the use of PET imaging as a biomarker in therapeutic drug trials and in personalized medicine. He has many years experience, background, and knowledge of the regulatory approval process for PET imaging agents. He has filed eight Investigational New Drug (IND) applications during his academic career. His own research activities include the use of PET imaging techniques to assess malignancy in both basic science studies and clinical trials; assessment of early response to cancer therapy; and in studying disorders of the nervous system. Other focuses of his research are in the use of PET imaging to understand cancer-associated physiologic changes and complications including the effects of chemotherapy on cognitive function, cardiac function, and muscle weakness/fatigue.

His bibliography includes 138 manuscripts, 18 book chapters, and 205 abstracts. He serves on four editorial boards including the Journal of Nuclear Medicine, Molecular Imaging and Biology, Molecular Imaging, and Radiology and has a long history of extramural funding.

Selected Publications

• Foster NL, Wang AY, Tasdizen T, Fletcher PT, Hoffman JM, Koeppe RA. Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer’s disease. Alzheimer Dement 2008; 4(S1):S29-36

• Turner RS, Grafton ST, McIntosh AR, DeLong MR, Hoffman JM. The Functional Anatomy of Parkinsonian Bradykinesia. NeuroImage, 19(1) 163-179, 2003

• Howell LL, Hoffman JM, Votaw JR,Landrum AM, Wilcox KM, Lindsey KP.  Cocaine-Induced Brain Activation Determined by Positron Emission Tomography (PET) Neuroimaging in Concious Rhesus Monkeys.  Psychopharmacology  159(2): 154-160, 2002

• Deterding TA, Votaw JR, Wang CK, Eshima D, Eshima L, Kiel R, Malveux E, Camp VM, Votaw DB, Kilts CD, Goodman, MM, Hoffman JM.  Biodistribution and Radiation Dosimetry of the Dopamine Transporter Ligand:  2B-carbomethoxy-3B(4-chlorophenyl)-8-(2fluoroethyl)nortropane([18F]FECNT. J Nucl Med 42:376-381, 2001

• Schweitzer JB, Faber TL, Grafton ST, Tune LE, Hoffman JM, Kilts CD.  Alterations in the Functional Anatomy of Working Memory in Adult-Attention Deficit/Hyperactivity Disorder. Am. J Psychiat. 157(2):278-280, 2000

• Hoffman JM, Welsh-Bohmer KA, Hanson MW, Crain BJ, Hulette C, Earl N, Coleman RE.  FDG-PET Imaging in Pathologically Verified Dementia. J. Nucl. Med. 41(11)1920-1928, 2000.

• Sathian K, Simon TJ, Peterson S, Patel GA, Hoffman JM, Grafton ST.  Neural Evidence Linking Visual Object Enumeration and Attention.  J Cognitive Neuroscience 11:1,36-51, 1999

• Turner RS, Grafton ST, Votaw JR, DeLong MR, Hoffman JM.  Motor Subcircuits Mediating the Control of Movement Velocity:  A PET Study.  J Neurophysiology  80:  2162-2176, 1998

• Clower DM, Hoffman JM, Votaw JA, Faber TL, Woods RP, Alexander GE.  Selective Activation of Posterior Parietal Cortex During the Recalibration of Reaching that Accompanies Prism Adaptation.  Nature 383: 618-621, 1996.

• Hoffman JM, Rasey JS, Spence AM, Shaw DW, and Krohn KA:  Binding of the Hypoxia Tracer [3H]‑Misonidazole in Cerebral Ischemia.  Stroke. 18:No.1, 168‑176, 1987

• Mazziotta, JC, Phelps ME, Pahl JJ, Huang SC, Baxter LR, Riege WH, Hoffman JM, Kuhl DE, Lanto AB, Wapenski JA, Markham CH:  Cerebral Glucose Utilization Reductions in Clinically Asymptomatic Subjects at Risk for Huntington's disease. New England J of Medicine.  16:7, 357‑362, 1987.